Cargando…

Pulmonary artery enlargement predicts poor survival in patients with COPD: A meta‐analysis

No previous meta‐analysis has evaluated the relationship between pulmonary artery enlargement (PAE) measured by computed tomography (CT) and prognosis for patients with chronic obstructive pulmonary disease (COPD). Recently, several studies have suggested poor survival and reduced exercise capacity...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Huaqiao, Shu, Tingting, Wang, Lu, Yang, Lingzhi, Hu, Changchun, Du, Shanshan, Wei, Huang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262316/
https://www.ncbi.nlm.nih.gov/pubmed/35833098
http://dx.doi.org/10.1002/pul2.12099
_version_ 1784742468497965056
author Chen, Huaqiao
Shu, Tingting
Wang, Lu
Yang, Lingzhi
Hu, Changchun
Du, Shanshan
Wei, Huang
author_facet Chen, Huaqiao
Shu, Tingting
Wang, Lu
Yang, Lingzhi
Hu, Changchun
Du, Shanshan
Wei, Huang
author_sort Chen, Huaqiao
collection PubMed
description No previous meta‐analysis has evaluated the relationship between pulmonary artery enlargement (PAE) measured by computed tomography (CT) and prognosis for patients with chronic obstructive pulmonary disease (COPD). Recently, several studies have suggested poor survival and reduced exercise capacity in COPD patients with PAE on CT scan, but there were conflicting results. We aimed to assess the prognostic value of PAE‐CT in patients with COPD. Relevant studies were identified by searching major databases. Pooled outcomes were determined to assess the prognostic value of PAE‐CT in COPD patients. Eighteen studies including 5694 participants were included. PAE indicated higher mortality in COPD patients (odds ratio [OR] = 3.06; 95% confidence interval [95% CI]: 1.76–5.32; p < 0.0001), shorter 6‐minute walk distance (mean difference [MD] = −67.53 m; 95% CI: −85.98 to −49.08; p < 0.00001), higher pulmonary artery systolic pressure (MD = 15.65 mmHg; 95% CI: 13.20–18.11; p < 0.00001), longer length of hospital stay (MD = 2.92 days; 95% CI: 0.71–5.12; p = 0.009) and more severe symptom such as dyspnea (COPD Assessment Test MD = 3.14; 95% CI: 2.48–3.81; p < 0.00001). We also conducted a subgroup analysis regarding the lung function and blood gas analysis for a stable period and acute exacerbation of COPD patients. In conclusion, PAE is significantly associated with mortality, lower exercise tolerance, and poor quality of life in patients with COPD. PAE may serve as a novel imaging biomarker for risk stratification in patients with COPD in the future.
format Online
Article
Text
id pubmed-9262316
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92623162022-07-12 Pulmonary artery enlargement predicts poor survival in patients with COPD: A meta‐analysis Chen, Huaqiao Shu, Tingting Wang, Lu Yang, Lingzhi Hu, Changchun Du, Shanshan Wei, Huang Pulm Circ Research Articles No previous meta‐analysis has evaluated the relationship between pulmonary artery enlargement (PAE) measured by computed tomography (CT) and prognosis for patients with chronic obstructive pulmonary disease (COPD). Recently, several studies have suggested poor survival and reduced exercise capacity in COPD patients with PAE on CT scan, but there were conflicting results. We aimed to assess the prognostic value of PAE‐CT in patients with COPD. Relevant studies were identified by searching major databases. Pooled outcomes were determined to assess the prognostic value of PAE‐CT in COPD patients. Eighteen studies including 5694 participants were included. PAE indicated higher mortality in COPD patients (odds ratio [OR] = 3.06; 95% confidence interval [95% CI]: 1.76–5.32; p < 0.0001), shorter 6‐minute walk distance (mean difference [MD] = −67.53 m; 95% CI: −85.98 to −49.08; p < 0.00001), higher pulmonary artery systolic pressure (MD = 15.65 mmHg; 95% CI: 13.20–18.11; p < 0.00001), longer length of hospital stay (MD = 2.92 days; 95% CI: 0.71–5.12; p = 0.009) and more severe symptom such as dyspnea (COPD Assessment Test MD = 3.14; 95% CI: 2.48–3.81; p < 0.00001). We also conducted a subgroup analysis regarding the lung function and blood gas analysis for a stable period and acute exacerbation of COPD patients. In conclusion, PAE is significantly associated with mortality, lower exercise tolerance, and poor quality of life in patients with COPD. PAE may serve as a novel imaging biomarker for risk stratification in patients with COPD in the future. John Wiley and Sons Inc. 2022-07-01 /pmc/articles/PMC9262316/ /pubmed/35833098 http://dx.doi.org/10.1002/pul2.12099 Text en © 2022 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Chen, Huaqiao
Shu, Tingting
Wang, Lu
Yang, Lingzhi
Hu, Changchun
Du, Shanshan
Wei, Huang
Pulmonary artery enlargement predicts poor survival in patients with COPD: A meta‐analysis
title Pulmonary artery enlargement predicts poor survival in patients with COPD: A meta‐analysis
title_full Pulmonary artery enlargement predicts poor survival in patients with COPD: A meta‐analysis
title_fullStr Pulmonary artery enlargement predicts poor survival in patients with COPD: A meta‐analysis
title_full_unstemmed Pulmonary artery enlargement predicts poor survival in patients with COPD: A meta‐analysis
title_short Pulmonary artery enlargement predicts poor survival in patients with COPD: A meta‐analysis
title_sort pulmonary artery enlargement predicts poor survival in patients with copd: a meta‐analysis
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262316/
https://www.ncbi.nlm.nih.gov/pubmed/35833098
http://dx.doi.org/10.1002/pul2.12099
work_keys_str_mv AT chenhuaqiao pulmonaryarteryenlargementpredictspoorsurvivalinpatientswithcopdametaanalysis
AT shutingting pulmonaryarteryenlargementpredictspoorsurvivalinpatientswithcopdametaanalysis
AT wanglu pulmonaryarteryenlargementpredictspoorsurvivalinpatientswithcopdametaanalysis
AT yanglingzhi pulmonaryarteryenlargementpredictspoorsurvivalinpatientswithcopdametaanalysis
AT huchangchun pulmonaryarteryenlargementpredictspoorsurvivalinpatientswithcopdametaanalysis
AT dushanshan pulmonaryarteryenlargementpredictspoorsurvivalinpatientswithcopdametaanalysis
AT weihuang pulmonaryarteryenlargementpredictspoorsurvivalinpatientswithcopdametaanalysis